Skip to main content
SpringerLink
Log in

Treatment of Hypertension in the Metabolic Syndrome

  • Chapter
  • First Online:
The Metabolic Syndrome

  • 1984 Accesses

Abstract

The metabolic syndrome is a highly prevalent condition currently considered to be a cluster of metabolic and cardiovascular risk factors, including blood pressure elevation. A higher risk for progression from high normal blood pressure to hypertension has been observed in individuals with metabolic syndrome and, when hypertension is established, hypertension seems to confer a higher cardiovascular risk on top of the risk induced by blood pressure elevation itself. Therefore, assessment of metabolic syndrome components can result in a clinical utility strategy to manage hypertension based on individual risk.

In subjects with metabolic syndrome, intense lifestyle measures should be adopted and antihypertensive drug treatment instituted whenever blood pressure is ≥140/90 mmHg because subjects with metabolic syndrome have higher prevalence of multiple target organ damage and increased levels of inflammatory markers, which are associated with higher cardiovascular risk. The antihypertensive treatment should preferably consist of blockers of the renin–angiotensin system with the addition, when needed, of a calcium antagonist and/or a low dose thiazide diuretic. As the other cardiovascular risk factors like, for example, the other elements of the metabolic syndrome broaden the blood pressure ranges associated with increased cardiovascular risk, the blood pressure goal in subjects with metabolic syndrome is suggested to be 130/85 mmHg even in the absence of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al (2007) Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187

    Article  PubMed  CAS  Google Scholar 

  2. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A et al (2001) Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with noninsulin-dependent diabetes mellitus. Circulation 103:1238–1244

    Article  PubMed  CAS  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al (2003) National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572

    Article  PubMed  CAS  Google Scholar 

  4. American Diabetes Association (2005) Clinical practice recommendations 2005. Diabetes Care 28(Suppl 1):S1–S79

    Google Scholar 

  5. Lithell H (1993) Hypertension and hyperlipidemia. A review. Am J Hypertens 6:303S–308S

    Article  PubMed  CAS  Google Scholar 

  6. Messerli FH, Grossman E, Leonetti G (2004) Antihypertensive therapy and new onset diabetes. J Hypertens 22:1845–1847

    Article  PubMed  CAS  Google Scholar 

  7. Mancia G, Grassi G, Zanchetti A (2006) New-onset diabetes and antihypertensive drugs. J Hypertens 24:3–10

    Article  PubMed  CAS  Google Scholar 

  8. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K et al (2006) On behalf of the STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29:2592–2597

    Article  PubMed  CAS  Google Scholar 

  9. McTavish D, Campoli-Richards D, Sorkin EM (1993) Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45:232–258

    Article  PubMed  CAS  Google Scholar 

  10. Tzemos N, Lim PO, MacDonald TM (2001) Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104:511–514

    Article  PubMed  CAS  Google Scholar 

  11. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA et al (2004) GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227–2236

    Article  PubMed  CAS  Google Scholar 

  12. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT (2006) Influence of nevibolol and enalapril on metabolic parameters an arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 24:1397–1403

    Article  PubMed  CAS  Google Scholar 

  13. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G (2007) Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 25: 2463–2470

    Article  PubMed  CAS  Google Scholar 

  14. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) Hypothesis: betaadrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254

    Article  PubMed  CAS  Google Scholar 

  15. Horiuchi M, Mogi M, Iwai M (2006) Signaling crosstalk angiotensin II receptor subtypes and insulin. Endocr J 53:1–5

    Article  PubMed  CAS  Google Scholar 

  16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153

    Article  PubMed  CAS  Google Scholar 

  17. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al (2004) VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031

    Article  PubMed  CAS  Google Scholar 

  18. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA et al (2006) VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24:1405–1412

    Article  PubMed  CAS  Google Scholar 

  19. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G et al (2006) DREAM Trial Investigators Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562

    Article  PubMed  Google Scholar 

  20. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002

    Article  PubMed  CAS  Google Scholar 

  21. Di Filippo C, Lampa E, Tufariello E, Petronella P, Freda F, Capuano A, D’Amico M (2005) Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res 13:1909–1914

    Article  PubMed  Google Scholar 

  22. Ridker PM, Danielson E, Rifai N, Glynn RJ (2006) Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 48:73–79

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Odense University Hospital, Kloevervaenget 6, 5th floor, 5000, Odense C, Denmark

    Michael Hecht Olsen

Authors
  1. Michael Hecht Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Hecht Olsen .

Editor information

Editors and Affiliations

  1. Dept. Endocrinology, Odense University Hospital, Kloevervaenget 6 4, Odense C, 5000, Denmark

    Henning Beck-Nielsen

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Wien

About this chapter

Cite this chapter

Olsen, M.H. (2013). Treatment of Hypertension in the Metabolic Syndrome. In: Beck-Nielsen, H. (eds) The Metabolic Syndrome. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1331-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1331-8_13

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1330-1

  • Online ISBN: 978-3-7091-1331-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation